Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?
- PMID: 26944314
- PMCID: PMC5016239
- DOI: 10.1016/j.canlet.2016.02.035
Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?
Abstract
Adverse reactions in normal tissue after radiotherapy (RT) limit the dose that can be given to tumour cells. Since 80% of individual variation in clinical response is estimated to be caused by patient-related factors, identifying these factors might allow prediction of patients with increased risk of developing severe reactions. While inactivation of cell renewal is considered a major cause of toxicity in early-reacting normal tissues, complex interactions involving multiple cell types, cytokines, and hypoxia seem important for late reactions. Here, we review 'omics' approaches such as screening of genetic polymorphisms or gene expression analysis, and assess the potential of epigenetic factors, posttranslational modification, signal transduction, and metabolism. Furthermore, functional assays have suggested possible associations with clinical risk of adverse reaction. Pathway analysis incorporating different 'omics' approaches may be more efficient in identifying critical pathways than pathway analysis based on single 'omics' data sets. Integrating these pathways with functional assays may be powerful in identifying multiple subgroups of RT patients characterised by different mechanisms. Thus 'omics' and functional approaches may synergise if they are integrated into radiogenomics 'systems biology' to facilitate the goal of individualised radiotherapy.
Keywords: Gene expression microarrays; Genome-wide association studies; Normal-tissue reaction; Predictive tests; Radiotherapy; Single-nucleotide polymorphisms.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Figures



Similar articles
-
Radiogenomics - current status, challenges and future directions.Cancer Lett. 2016 Nov 1;382(1):127-136. doi: 10.1016/j.canlet.2016.01.035. Epub 2016 Jan 28. Cancer Lett. 2016. PMID: 26828014 Review.
-
Radiogenomics: the search for genetic predictors of radiotherapy response.Future Oncol. 2014 Dec;10(15):2391-406. doi: 10.2217/fon.14.173. Future Oncol. 2014. PMID: 25525847 Review.
-
Finding the genetic determinants of adverse reactions to radiotherapy.Clin Oncol (R Coll Radiol). 2014 May;26(5):301-8. doi: 10.1016/j.clon.2014.02.001. Epub 2014 Apr 1. Clin Oncol (R Coll Radiol). 2014. PMID: 24702740 Review.
-
Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.Cancer Discov. 2014 Feb;4(2):155-65. doi: 10.1158/2159-8290.CD-13-0197. Epub 2014 Jan 17. Cancer Discov. 2014. PMID: 24441285 Free PMC article. Review.
-
Cohort Studies and Multi-omics Approaches to Low-Dose Ionizing Radiation-Induced Cardiovascular Disease: A Comprehensive Review.Cardiovasc Toxicol. 2025 Jan;25(1):148-165. doi: 10.1007/s12012-024-09943-5. Epub 2024 Nov 13. Cardiovasc Toxicol. 2025. PMID: 39538046 Review.
Cited by
-
Genome-Wide Association Study of Susceptibility Loci for Radiation-Induced Brain Injury.J Natl Cancer Inst. 2019 Jun 1;111(6):620-628. doi: 10.1093/jnci/djy150. J Natl Cancer Inst. 2019. PMID: 30299488 Free PMC article.
-
One Size Fits All: Does the Dogma Stand in Radiation Oncology?EBioMedicine. 2016 Aug;10:19-20. doi: 10.1016/j.ebiom.2016.07.025. Epub 2016 Jul 20. EBioMedicine. 2016. PMID: 27453323 Free PMC article. No abstract available.
-
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.Lancet Oncol. 2017 Feb;18(2):202-211. doi: 10.1016/S1470-2045(16)30648-9. Epub 2016 Dec 18. Lancet Oncol. 2017. PMID: 27993569 Free PMC article.
-
Recent advances in radiation oncology.Ecancermedicalscience. 2017 Nov 30;11:785. doi: 10.3332/ecancer.2017.785. eCollection 2017. Ecancermedicalscience. 2017. PMID: 29225692 Free PMC article. Review.
-
Individual Radiosensitivity in Oncological Patients: Linking Adverse Normal Tissue Reactions and Genetic Features.Front Oncol. 2019 Oct 1;9:987. doi: 10.3389/fonc.2019.00987. eCollection 2019. Front Oncol. 2019. PMID: 31632918 Free PMC article.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69–90. - PubMed
-
- Safwat A, Bentzen SM, Turesson I, Hendry JH. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys. 2002;52(1):198–204. - PubMed
-
- Tucker SL, Turesson I, Thames HD. Evidence for individual differences in the radiosensitivity of human skin. Eur J Cancer. 1992;28A(11):1783–91. - PubMed
-
- Turesson I. Individual variation and dose dependency in the progression rate of skin telangiectasia. Int J Radiat Oncol Biol Phys. 1990;19(6):1569–74. - PubMed
-
- Potten CS. Cell cycles in cell hierarchies. International journal of radiation biology and related studies in physics, chemistry, and medicine. 1986;49(2):257–78. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical